Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis
about
Personalized medicine: hope or hype?P2Y12-ADP receptor antagonists: Days of future and pastPersonalized antiplatelet therapy with P2Y12 receptor inhibitors: benefits and pitfallsCardiovascular pharmacogenomics: current status and future directionsThe pharmacogenetic control of antiplatelet response: candidate genes and CYP2C19Personalized antiplatelet and anticoagulation therapy: applications and significance of pharmacogenomicsClopidogrel and proton pump inhibitors--where do we stand in 2012?Pharmacogenomics and cardiovascular diseasePharmacogenomics of anti-platelet therapy: how much evidence is enough for clinical implementation?ABC Transport Proteins in Cardiovascular Disease-A Brief Summary.Genetic susceptibility to ischemic stroke.Clopidogrel: the data, the experience, and the controversies.Use of genetic data to guide therapy in arterial disease.Genetic testing for CYP450 polymorphisms to predict response to clopidogrel: current evidence and test availability. Application: pharmacogenomics.Development of a multiplex and cost-effective genotype test toward more personalized medicine for the antiplatelet drug clopidogrel.Potential Usefulness of Clopidogrel Pharmacogenetics in Cerebral Endovascular Procedures and Carotid Artery Stenting.Guided antithrombotic therapy: current status and future research direction: report on a National Heart, Lung and Blood Institute working group.Cytochrome p450 gene variants, race, and mortality among clopidogrel-treated patients after acute myocardial infarction.Antiplatelet drug interactions with proton pump inhibitorsGenetic regulation of platelet receptor expression and function: application in clinical practice and drug development.Combined influence of proton-pump inhibitors, calcium-channel blockers and CYP2C19*2 on on-treatment platelet reactivity and on the occurrence of atherothrombotic events after percutaneous coronary intervention.Platelet function monitoring in patients on clopidogrel: What should we learn from GRAVITAS?Mutational analysis clopidogrel resistance and platelet function in patients scheduled for coronary artery bypass grafting.Pharmacogenetics and clopidogrel response in patients undergoing percutaneous coronary interventions.Effects of cytochrome P450 2C19 and paraoxonase 1 polymorphisms on antiplatelet response to clopidogrel therapy in patients with coronary artery diseaseABCB1 C3435T polymorphism and response to clopidogrel treatment in coronary artery disease (CAD) patients: a meta-analysisCytochrome P450 2C19*2 polymorphism in patients with stable coronary heart disease and risk for secondary cardiovascular disease events: results of a long-term follow-up study in routine clinical care.The genetics of common variation affecting platelet development, function and pharmaceutical targeting.Platelet function in patients with diabetes mellitus: from a theoretical to a practical perspectiveCardiovascular pharmacogenomicsMonitoring Residual Platelet Activity Among Patients With Acute Coronary Syndrome Post-PCI by Modified Impedance Whole Blood Platelet Aggregation and Release Method.Pharmacokinetics and pharmacodynamics following maintenance doses of prasugrel and clopidogrel in Chinese carriers of CYP2C19 variants.Critical appraisal of ticagrelor in the management of acute coronary syndromeIdentification of CYP2C19*4B: pharmacogenetic implications for drug metabolism including clopidogrel responsiveness.Association of Cytochrome P450 Genetic Variants with Clopidogrel Resistance and Outcomes in Acute Ischemic Stroke.Interaction analysis between genetic polymorphisms and pharmacodynamic effect in patients treated with adjunctive cilostazol to dual antiplatelet therapy: results of the ACCEL-TRIPLE (Accelerated Platelet Inhibition by Triple Antiplatelet Therapy AcMulti-ethnic distribution of clinically relevant CYP2C genotypes and haplotypes.Impact of CYP2C19 Variants on Clinical Efficacy of Clopidogrel and 1-Year Clinical Outcomes in Coronary Heart Patients Undergoing Percutaneous Coronary Intervention.The intelligent use and clinical benefits of electronic medical records in multiple sclerosisPharmacodynamic effect of cilostazol plus standard clopidogrel versus double-dose clopidogrel in patients with type 2 diabetes undergoing percutaneous coronary intervention
P2860
Q24289193-FCEAA733-FA99-422A-8330-6CC4737929CCQ26745619-4E315A83-CA9E-4B8E-A181-4CC77F214377Q26775125-C7DFDD94-5909-4A72-BF1E-936019C9FC5AQ26801183-6944D330-C914-4B9C-BAF1-4572F191E1EDQ26801867-F5256140-874C-47FB-AF81-8DF61687D0BDQ26822796-980D7C41-8821-4BD9-B7B8-5161BE599D31Q26825728-C858671D-F22E-41AE-9425-F4B5C8D42724Q26997380-200D61EE-3890-43F2-9050-A31556EB0E8CQ27022443-2DD0227B-A8D1-4884-92D0-7536DD23D2A0Q30313271-833AF6E1-7D57-46A8-B45F-3BB2B6AF9A00Q30414709-74CB7F4D-A5A1-43E2-82CA-7BBDBABDD3DCQ30573045-5014E2AB-7FBD-4C23-95E2-BC0A6B36851FQ30978916-DF8F065C-35B9-4084-9393-1238EA68AD07Q33704998-620A36D9-4BCB-4768-A2EC-836D3662BB44Q33755635-4FD25359-79AB-4291-8FD1-30CA2B271DBBQ33818356-BE7F15BD-8DD3-4B3C-ACE4-3F89BAAD6C96Q33863833-E5908BB7-1B09-4F3D-AFF7-CF6686F8780AQ33923341-6FDFD1CB-900B-42F5-9AF0-11D6F1B6D84FQ33948811-AD132919-BC00-4BC7-BE04-AA5203699184Q33988457-2DE52C9C-7275-40EC-B11A-FA29C3465959Q33997642-567802E5-015A-4AC0-ADA2-1B30CB6E334BQ34035039-C94969E0-014D-45E8-942E-EFA0A07884E0Q34108764-D3C5EF3A-6D90-455C-9309-78653DE1C19CQ34161006-A8052A9E-C79B-4962-9609-ED897ABA62D0Q34352152-8349321D-FE71-4683-BB50-31AAA1F163A1Q34441355-D52FD679-D398-4CDE-88ED-5EAF76489C1BQ34975032-001CC92A-3A70-4FE9-8370-FCFE920E5937Q35149898-E316045C-8CD1-4D75-A374-8D379FB032C0Q35174193-237E366E-BAC6-4FA6-91B4-D4A7FD4665DFQ35447163-F08AE55B-8206-4301-8972-1B493D3FC7DAQ35635382-59ACAB85-2ABD-4733-AA11-136D85C45540Q35640465-95F5F157-C883-4762-8417-554356399345Q35660767-3EED821D-3821-482A-BA63-6A85EEE87F68Q35846595-39DB7607-110B-4E47-8E4E-6B3115FBF7F0Q35951677-1C44F353-4E8E-4AC9-90D5-24DC32143BAEQ36036395-6CEEDF24-3FAD-4D8D-AAA2-081AE9E7CB9CQ36094919-CFC28CC4-76AE-4416-9592-C89171483E04Q36216896-45C1B952-EC42-4C46-875A-34DE5C73B9ADQ36263526-4D004734-6AA9-447A-9A2E-C7F669929A09Q36334515-A981625E-5DAF-4CE8-BB4B-18EDDDA07637
P2860
Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis
description
2010 nî lūn-bûn
@nan
2010 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Genetic variants in ABCB1 and ...... al: a pharmacogenetic analysis
@ast
Genetic variants in ABCB1 and ...... al: a pharmacogenetic analysis
@en
Genetic variants in ABCB1 and ...... al: a pharmacogenetic analysis
@nl
type
label
Genetic variants in ABCB1 and ...... al: a pharmacogenetic analysis
@ast
Genetic variants in ABCB1 and ...... al: a pharmacogenetic analysis
@en
Genetic variants in ABCB1 and ...... al: a pharmacogenetic analysis
@nl
prefLabel
Genetic variants in ABCB1 and ...... al: a pharmacogenetic analysis
@ast
Genetic variants in ABCB1 and ...... al: a pharmacogenetic analysis
@en
Genetic variants in ABCB1 and ...... al: a pharmacogenetic analysis
@nl
P2093
P2860
P50
P1433
P1476
Genetic variants in ABCB1 and ...... al: a pharmacogenetic analysis
@en
P2093
Jessica L Mega
Joseph R Walker
Marc S Sabatine
Sandra L Close
Stephen D Wiviott
P2860
P304
P356
10.1016/S0140-6736(10)61273-1
P407
P577
2010-10-01T00:00:00Z